NCT00519896View on ClinicalTrials.gov

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

May 31, 2015

Study Completion Date

September 30, 2015

Conditions
Recurrent Thyroid CancerStage IVA Follicular Thyroid CancerStage IVA Papillary Thyroid CancerStage IVB Follicular Thyroid CancerStage IVB Papillary Thyroid CancerStage IVC Follicular Thyroid CancerStage IVC Papillary Thyroid CancerThyroid Gland Medullary Carcinoma
Interventions
DRUG

sunitinib malate

Given PO

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT00519896 - Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer | Biotech Hunter | Biotech Hunter